A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Recruiting

PDS with RanibizumabA Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Sponsor:

Genentech, Inc.

Code:

NCT04853251

Conditions

Neovascular Age-related Macular Degeneration

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

PDS Implant With Ranibizumab 100 mg/ml

LUCENTIS (Ranibizumab Injection)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-06. This information was provided to ClinicalTrials.gov by Genentech, Inc. on 2025-10-24.